Javid J. Moslehi

Javid J. Moslehi's AcademicInfluence.com Rankings

Javid J. Moslehi

Philosophy

#7347

World Rank

#10548

Historical Rank

Logic

#4405

World Rank

#5693

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Javid J. Moslehi's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Javid J. Moslehi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Javid J. Moslehi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Fulminant Myocarditis with Combination Immune Checkpoint Blockade. (2016) (1389)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis (2018) (1232)
Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging (2013) (1074)
Telomere dysfunction induces metabolic and mitochondrial compromise (2011) (960)
Nucleated conformational conversion and the replication of conformational information by a prion determinant. (2000) (948)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. (2018) (815)
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. (2017) (753)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. (2018) (549)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis (2018) (518)
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. (2020) (427)
Cardiovascular Toxic Effects of Targeted Cancer Therapies. (2016) (406)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. (2015) (329)
Roles of interferon-gamma and interleukin-4 in murine lupus. (1997) (317)
Immune checkpoint inhibitors and cardiovascular toxicity. (2018) (301)
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. (2008) (273)
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells (2017) (265)
Recognition and Initial Management of Fulminant Myocarditis (2020) (262)
Cardiovascular toxicities associated with immune checkpoint inhibitors (2019) (250)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. (2019) (237)
cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism (2004) (212)
Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology (2019) (202)
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy (2020) (201)
An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells (2002) (188)
MicroRNA-26a Regulates Pathological and Physiological Angiogenesis by Targeting BMP/SMAD1 Signaling (2013) (183)
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study (2019) (183)
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials (2017) (182)
Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. (2017) (171)
Telomere dysfunction induces metabolic and mitochondrial compromise (2011) (168)
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. (2020) (164)
Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. (2013) (161)
Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease (2018) (159)
Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. (2014) (157)
Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. (2012) (157)
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. (2011) (155)
A Feedback Loop Involving the Phd3 Prolyl Hydroxylase Tunes the Mammalian Hypoxic Response In Vivo (2009) (148)
Ventricular arrhythmias and sudden death in patients taking ibrutinib. (2017) (147)
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). (2022) (144)
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. (2015) (143)
Emerging paradigms in cardiomyopathies associated with cancer therapies. (2013) (137)
Immune-checkpoint inhibitors: long-term implications of toxicity (2022) (135)
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy (2010) (130)
Cardiovascular Toxicities Associated With Ibrutinib. (2019) (129)
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). (2022) (128)
Smoldering myocarditis following immune checkpoint blockade (2017) (128)
Cardiovascular Toxicities Associated with Cancer Immunotherapies (2017) (118)
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology (2020) (118)
Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. (2019) (113)
Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis (2019) (111)
Cardio-Oncology: Vascular and Metabolic Perspectives A Scientific Statement From the American Heart Association (2019) (111)
Telomeres and Mitochondria in the Aging Heart (2012) (110)
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. (2019) (109)
Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase (2014) (106)
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis (2019) (105)
Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. (2018) (103)
Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. (2011) (103)
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. (2013) (99)
Immune Checkpoint Inhibitor-Associated Myositis. (2018) (99)
Perforin protects against autoimmunity in lupus-prone mice. (1998) (98)
Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. (2018) (98)
Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer (2016) (94)
Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. (2019) (93)
Management of antiangiogenic therapy-induced hypertension. (2012) (91)
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action (2018) (88)
Hematologic Complications of Immune Checkpoint Inhibitors (2019) (88)
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin (2020) (87)
Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity (2002) (85)
Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. (2015) (84)
A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. (2020) (82)
Yeast prion [psi +] and its determinant, Sup35p. (1999) (81)
NCCN guidelines® insights survivorship, version 1.2016 featured updates to the NCCN Guidelines (2016) (80)
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection (2016) (79)
Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (75)
Paragangliomas: Etiology, Presentation, and Management (2009) (74)
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review (2017) (71)
Cancer-drug discovery and cardiovascular surveillance. (2013) (70)
Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature. (2008) (69)
Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. (2014) (68)
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice (2014) (68)
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis (2018) (67)
Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy (2019) (65)
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection (2016) (63)
The cardiovascular perils of cancer survivorship. (2013) (63)
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. (2016) (61)
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (61)
Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes (2018) (60)
Reversible cardiomyopathy associated with sunitinib and sorafenib. (2011) (60)
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. (2016) (57)
Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes. (2019) (57)
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors (2019) (57)
Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients (2020) (57)
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase (2020) (56)
Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment (2018) (55)
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. (2020) (54)
Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. (2018) (53)
NCCN Guidelines Insights: Survivorship, Version 1.2016. (2020) (53)
NCCN Guidelines Insights: Survivorship, Version 2.2020. (2020) (52)
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. (2020) (51)
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses (2020) (51)
Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. (2021) (51)
Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. (2019) (51)
COVID-19 and immune checkpoint inhibitors: initial considerations (2020) (49)
Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease (2020) (47)
Treatment of erythropoietin deficiency in mice with systemically administered siRNA. (2012) (46)
Survivorship: healthy lifestyles, version 2.2014. (2014) (46)
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma (2017) (43)
Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma (2020) (42)
Erratum: Telomere dysfunction induces metabolic and mitochondrial compromise (Nature (2011) 470 (359-365)) (2011) (41)
Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. (2017) (41)
Immune Checkpoint Inhibitors Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. (2020) (41)
Cardiovascular Complications of Novel Multiple Myeloma Treatments (2016) (41)
The cancer patient and cardiology (2020) (39)
Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway (2014) (38)
Survivorship: Cognitive function, Version 1.2014; Clinical practice guidelines in oncology (2014) (38)
QT Prolongation and Oncology Drug Development. (2015) (37)
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors (2018) (36)
Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. (2021) (36)
Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review (2019) (36)
A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. (2014) (36)
NCCN Guidelines Insights: Survivorship, Version 2.2019. (2019) (34)
Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome. (2014) (34)
Survivorship, version 2.2019 featured updates to the NCCN guidelines (2019) (33)
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care. (2019) (33)
Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. (2016) (33)
ABCDE steps to prevent heart disease in breast cancer survivors. (2014) (32)
Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK. (2020) (32)
Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology. (2014) (31)
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. (2020) (31)
Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. (2021) (29)
Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens (2019) (29)
Grounding Cardio-Oncology in Basic and Clinical Science. (2017) (29)
Survivorship: cognitive function, version 1.2014. (2014) (28)
Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy (2020) (28)
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies (2021) (27)
Influence of antigen organization on the development of lupus autoantibodies. (1998) (27)
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents (2020) (26)
Survivorship: fatigue, version 1.2014. (2014) (26)
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. (2020) (25)
Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis. (2018) (25)
Identification of anticancer drugs associated with atrial fibrillation - analysis of the WHO pharmacovigilance database. (2020) (24)
Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. (2021) (24)
Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it? (2018) (24)
Cardio-Immuno-Oncology. (2020) (23)
In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers (2018) (23)
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. (2020) (23)
Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic (2018) (23)
Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management (2019) (23)
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy (2020) (23)
Survivorship: sleep disorders, version 1.2014. (2014) (23)
T cells specific for α-myosin drive immunotherapy-related myocarditis (2022) (23)
Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis. (2019) (22)
Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis (2021) (22)
Book Review: Braunwald's Heart Disease: A Textbook of Cardiovascular Disease (2007) (22)
Survivorship, Version 1.2021. (2021) (21)
Survivorship: Fatigue, Version 1.2014: Clinical Practice Guidelines in Oncology (2014) (21)
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma (2018) (21)
Myocarditis with Immune Checkpoint Blockade. (2017) (20)
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy (2019) (20)
Mortality and Pre‐Hospitalization use of Renin‐Angiotensin System Inhibitors in Hypertensive COVID‐19 Patients (2020) (20)
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. (2021) (19)
21st Century Cardio-Oncology (2016) (19)
Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary. (2014) (19)
Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers. (2018) (19)
Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study (2018) (18)
Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need. (2019) (18)
Heart Failure and Breast Cancer Therapies: Moving Towards Personalized Risk Assessment (2014) (18)
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. (2019) (18)
Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective. (2020) (18)
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis (2021) (17)
Abstract 14587: Proarrhythmic Effects of Ibrutinib, a Clinically Approved Inhibitor of Bruton’S Tyrosine Kinase (BTK) Used in Cancer Therapy (2015) (17)
Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. (2020) (17)
Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database (2022) (17)
Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. (2019) (16)
Harnessing big data to characterize immune-related adverse events (2022) (16)
Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM) (2013) (16)
Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. (2016) (15)
Heart Slice Culture System Reliably Demonstrates Clinical Drug-Related Cardiotoxicity (2020) (15)
Survivorship: immunizations and prevention of infections, version 2.2014. (2014) (15)
Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity. (2020) (14)
Global Longitudinal Strain in Cardio-Oncology. (2021) (14)
Cardio-Oncology (2017) (14)
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept (2022) (14)
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients (2021) (14)
Cancer Therapy-Induced Cardiovascular Toxicity: New Problems and Old Drugs. (2019) (13)
Breast cancer therapies and cardiomyopathy. (2012) (13)
Cardio-Oncology: It Takes Two to Translate (2013) (13)
Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation. (2020) (13)
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial (2022) (13)
Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. (2019) (13)
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (2019) (13)
Survivorship: screening for cancer and treatment effects, version 2.2014. (2014) (13)
Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment. (2019) (13)
Loss of the melanocortin-4 receptor in mice causes dilated cardiomyopathy (2017) (12)
Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. (2015) (12)
Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis (2020) (12)
LATE GADOLINIUM ENHANCEMENT IN PATIENTS WITH MYOCARDITIS FROM IMMUNE CHECKPOINT INHIBITORS (2019) (12)
Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study (2020) (11)
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase (2018) (10)
Assessing cardiac safety in oncology drug development (2019) (10)
Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study (2018) (10)
Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy (2020) (10)
Roles of Interferon-g and Interleukin-4 in Murine Lupus (2013) (10)
Survivorship: pain version 1.2014. (2014) (10)
Fulminant Myocarditis: Evolving Diagnosis, Evolving Biology, Evolving Prognosis. (2019) (10)
The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases (2017) (10)
The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. (2019) (10)
Sex-Specific Cardiovascular Risks of Cancer and Its Therapies (2022) (9)
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer (2022) (9)
Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis (2022) (9)
Chimeric antigen receptor T‐cells safety: A pharmacovigilance and meta‐analysis study (2021) (9)
Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer. (2019) (8)
Solid organ transplant rejection associated with immune-checkpoint inhibitors. (2020) (8)
Report from session I the Second International Colloquium on Cardio-oncology, Krakow, Poland: Mechanisms and clinical course of cardiovascular toxicity of cancer treatment (2019) (8)
Age-Related Considerations in Cardio-Oncology (2020) (8)
Comparative Transcriptomics of Ex Vivo, Patient-Derived Endothelial Cells Reveals Novel Pathways Associated With Type 2 Diabetes Mellitus (2019) (8)
Cardiology patient page. Breast cancer chemotherapy and your heart. (2014) (6)
Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. (2021) (6)
18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. (2022) (6)
The challenge of cross-trial comparisons using limited data (2014) (6)
Cancer cachexia: getting to the heart of the matter. (2019) (6)
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. (2019) (6)
High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy (2021) (6)
Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program (2022) (6)
You can't run from inflammation: lower extremity ischemia, hypoxia signaling, and macrophage subtypes. (2012) (6)
Implementation of Cardio-Oncology Training for Cardiology Fellows (2020) (6)
Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors. (2020) (5)
Reporting of immune checkpoint inhibitor-associated myocarditis – Authors' reply (2018) (5)
Catabolism by Phosphodiesterase 5 A Regulates Cardiac Adrenergic Stimulation (2004) (5)
PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation. (2021) (5)
Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial (2021) (5)
Real-time three-dimensional transoesophageal echocardiography enables preoperative pulmonary valvulopathy assessment. (2014) (5)
Anticoagulation Strategies in Patients With Cancer (2019) (5)
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. (2023) (4)
Cardio-Oncology: Vascular Endothelial Growth Factor Inhibitors, Salt, and Macrophages: A Complicated Interaction. (2017) (4)
Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy (2018) (4)
Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) (2020) (4)
Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients. (2018) (4)
Inflammation begets inflammation: cancer and acute MI. (2020) (4)
Vascular Impact of Cancer Therapies (2021) (4)
The forgotten right ventricle in cardio-oncology (2019) (4)
Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis (2022) (4)
High-grade heart block associated with ibrutinib therapy (2021) (3)
RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets. (2021) (3)
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies (2017) (3)
MYOCARDITIS AND RHABDOMYOLYSIS INCIDENCE WITH IMMUNE CHECKPOINT INHIBITORS (2017) (3)
Left ventricular mass by cardiac magnetic resonance imaging and adverse cardiovascular outcomes in patients treated with anthracycline-based chemotherapy (2012) (3)
Cytotoxic T cells specific for alpha-myosin drive immunotherapy related myocarditis (2022) (3)
Expanding the Therapeutic World of Tryptophan Metabolism. (2022) (3)
Abstract 12978: Identification of Cardiovascular Adverse Effects Associated With Midostaurin - A WHO Pharmacovigilance Database Analysis (2020) (2)
Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer (2017) (2)
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions (2022) (2)
Molecular characterization of immune-related severe adverse events (irSAE). (2017) (2)
Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients (2020) (2)
Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. (2020) (2)
ACUTE HYPOXIA-INDUCIBLE FACTOR EGLN1 INACTIVATION PROTECTS AGAINST ISCHEMIA-REPERFUSION INJURY BY REGULATION OF GLUCOSE OXIDATION AND REACTIVE OXYGEN SPECIES GENERATION (2013) (2)
Abstract 4728: Apoptotic priming is regulated by a developmental program and predisposes children to therapy-induced toxicity (2015) (2)
Vascular medicine and cardio-oncology – A new, evolving clinical frontier (2020) (2)
Abstract 17218: Radiation Therapy is not Associated With Incident Atrial Fibrillation in Patients With Thoracic Cancer (2015) (2)
AGS and NIA bench‐to bedside conference summary: Cancer and cardiovascular disease (2022) (2)
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. (2022) (2)
Novel mechanism in cardiac injury: immune checkpoints (2020) (2)
Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism (2022) (2)
Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis (2017) (1)
Sildenafil Inhibits Cardiac Hypertrophy In Vivo: Role of the RhoA/rho Kinase Pathway (2005) (1)
Comorbidities: Cardiovascular disease and breast cancer (2018) (1)
Abstract 20758: Chemotherapy Treatment Increases the Risk of Developing Atrial Fibrillation in Breast Cancer (2016) (1)
Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database (2022) (1)
Role of PD-L1 in heart transplant rejection (2020) (1)
Incidence and risk of congestive heart failure risk in renal cell cancer (RCC) and non-RCC patients treated with sunitinib. (2011) (1)
P1591Cardiovascular toxicity of ibrutinib: a pharmacovigilance study (2019) (1)
Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma (2017) (1)
Hypertension Grand Rounds Management of Antiangiogenic Therapy-Induced Hypertension (2012) (1)
Tissue is the Issue, Even During a Pandemic. (2020) (1)
Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis (2011) (1)
Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy–induced toxicities (2022) (1)
Ventricular Arrhythmias and Sudden Death in Patients Taking Ibrutinib (2016) (1)
Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. (2022) (1)
Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study (2020) (1)
Mortality and Pre-Hospitalization Use of Renin-Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID-19). (2020) (1)
Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma (2015) (1)
Abstract 17397: Cardiac Dysfunction Resulting From Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway in Cancer Patients (2013) (0)
Author response: Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study (2018) (0)
Loss of PHD Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy (2010) (0)
Standing at the Crossroads. (2021) (0)
Machine Learning Modeling to Support Cardio-Oncology Medical Practice (2022) (0)
Abstract IA21: Immune Checkpoint Inhibitor-Associated Myocarditis: Learning from mice and humans (2022) (0)
Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada. (2022) (0)
Multi-Disciplinary Management in Rectal Cancer Survivorship: A Clinical Practice Review (2023) (0)
Roles of Interferon- (cid:103) and Interleukin-4 in Murine Lupus (1997) (0)
Evaluating the utility of baseline cardiac function assessment in early-stage breast cancer treatment. (2014) (0)
Abstract 18114: The Impact of Androgen Deprivation Therapy on One-Year Mortality in a Large Prostate Cancer Registry With Cardiovascular Risk Factors (2016) (0)
Clonal Hematopoiesis at Crossroads of Aging, Cardiovascular Diseases, and Cancer: JACC Topic of the Week (2019) (0)
Predictors of steroid-refractory immune checkpoint inhibitor associated myocarditis (2020) (0)
Editorial: Recent Advances in Cardiotoxicity Testing (2021) (0)
Addressing cardiovascular complications of BTK inhibitors. (2023) (0)
Reply to S. Rossi et al and P. Palassin et al. (2022) (0)
THE ASSOCIATION OF THE AMERICAN HEART ASSOCIATION'S LIFE'S SIMPLE 7 WITH INCIDENT CANCER IN THE SOUTHERN COMMUNITY COHORT STUDY (2016) (0)
Abstract P3074: Immune Checkpoint Inhibition Reshapes Cardiac Immune Landscape Through Crosstalk Between Macrophage And T-cell (2022) (0)
Abstract 15890: ACEI and ARB Use Modulates Blood Pressure Response During Initiation of Vascular Endothelial Growth Factor Receptor Inhibition (2018) (0)
PREDICTORS OF DEVELOPMENT OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN PATIENTS RECEIVING ANTHRACYCLINES (2016) (0)
Abstract 11267: Ibrutinib Treatment Results in Arrhythmia in Atrial-Specific Human Ipsc-Derived Cardiomyocytes (2021) (0)
RELATIONSHIP OF CORONARY VASOMOTOR FUNCTION TO MEAN RADIATION DOSE TO THE HEART IN CANCER SURVIVORS (2014) (0)
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology (2023) (0)
Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma. (2022) (0)
Single-nuclear RNA sequencing of endomyocardial biopsies identifies persistence of donor-recipient chimerism with distinct signatures in severe cardiac allograft vasculopathy (2022) (0)
O.21Immune checkpoint inhibitor-associated myositis: a new entity with a poor prognosis (2019) (0)
Abstract 588: Advanced molecular characterization of severe autoimmune toxicities associated with checkpoint inhibitor therapies (2017) (0)
Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133]. (2019) (0)
Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis (2023) (0)
Abstract 14843: Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Associated Myocarditis (2020) (0)
Diagnosis and Treatment of Acute Myocarditis: A Review. (2023) (0)
A Pilot Study of Associations Between the Occurrence of Palpitations and Cytokine Gene Variations in Women Prior to Breast Cancer Surgery (2022) (0)
P2597Heart failure and atrial tachyarrhythmia on abiraterone: a characterization using pharmacovigilance databases (2019) (0)
CLINICAL SIGNIFICANCE OF PERICARDIAL EFFUSION IN PATIENTS HOSPITALIZED WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED MYOCARDITIS (2022) (0)
Cancercachexia: getting to the heart of the matter (2013) (0)
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis (2019) (0)
Maturation and activation of T cells (2021) (0)
Fulminant Giant Cell Myocarditis Is Associated With Poor Outcomes (2020) (0)
Cardiovascular Health and Risk Management in Cancer Survivors (2020) (0)
805 Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice (2021) (0)
Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors (2019) (0)
Characterizing toxicities, body composition, and health-related quality of life (HRQoL) among long-term survivors treated with anti-PD-1. (2020) (0)
Abstract 14896: Cardiovascular Events and Healthcare Utilization Among Long-term Adult Cancer Survivors Relative to Comorbidity-matched Controls (2017) (0)
Author response: Loss of the melanocortin-4 receptor in mice causes dilated cardiomyopathy (2017) (0)
Many cancer survivors experience menopaus-NCCN Survivorship , Version 2 . 2017 Clinical Practice Guidelines in Oncology (2017) (0)
ECHOCARDIOGRAPHIC FEATURES OF IMMUNE CHECKPOINT INHIBITOR ASSOCIATED MYOCARDITIS AND THEIR ASSOCIATION WITH ADVERSE OUTCOMES (2021) (0)
Divergent Roles for RhoA and Rho Kinase in Cardiac Hypertrophy and the Progression to Heart Failure (2005) (0)
Abstract 17773: Baseline Cardiovascular Disease, Risk Factors, and Subsequent Changes Among Newly Diagnosed Prostate Cancer Patients (2016) (0)
Abstract IA10: Immune checkpoint inhibitor-associated cardiotoxicities: Learning from mice and humans (2020) (0)
Tom Force (1951–2020) (2020) (0)
18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis (2021) (0)
Response by Salem et al to Letter Regarding Article, "Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes". (2020) (0)
Reply to S. Tan et al. (2022) (0)
Abstract 16056: Acute HIF Prolyl Hydroxylase 2 Inactivation Confers Protection Against Myocardial Ischemic Reperfusion Injury (2011) (0)
Circulating immune checkpoints predict heart failure outcomes (2023) (0)
The next big questions in cancer research (2023) (0)
Abstract 15365: Natural History of Immune Checkpoint Inhibitor Associated Myocarditis With Preserved Ejection Fraction (2020) (0)
P6590Androgenic effects on ventricular repolarization: a translational study from pharmacovigilance databases to iPSC-cardiomyocytes (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Javid J. Moslehi?

Javid J. Moslehi is affiliated with the following schools:

Vanderbilt University
University of Oklahoma
University of Toronto
University of California, San Francisco